Patent classifications
C07D239/96
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
##STR00001##
2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS
The present invention relates to Na.sub.v1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X):
##STR00001##
wherein Y′, X′, B′, R.sup.1′, R.sup.2′, R.sup.3′, R.sup.5′, R.sup.6′, R.sup.7′, and z.sup.1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS
The present invention relates to Na.sub.v1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X):
##STR00001##
wherein Y′, X′, B′, R.sup.1′, R.sup.2′, R.sup.3′, R.sup.5′, R.sup.6′, R.sup.7′, and z.sup.1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
MASP-2 INHIBITORS AND METHODS OF USE
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
MASP-2 INHIBITORS AND METHODS OF USE
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases
Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL1 related disease or a disorder in a subject.
Heterocyclic compound
The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): ##STR00001##
wherein
Ar is a the partial structure (1) to the partial structure (5),
Q is a bivalent group selected from the group consisting of (Ia)-(If), and
B is a ring optionally having substituent(s),
or a salt thereof.
Heterocyclic compound
The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): ##STR00001##
wherein
Ar is a the partial structure (1) to the partial structure (5),
Q is a bivalent group selected from the group consisting of (Ia)-(If), and
B is a ring optionally having substituent(s),
or a salt thereof.
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1. ##STR00001##